Navneet S. Majhail|Elizabeth A. Murphy|Purushottam W. Laud|Jaime M. Preussler|Ellen M. Denzen|Beatrice Abetti|Alexia Adams|RaeAnne M. Besser|Linda J. Burns|Jan ?erný|Rebecca Drexler|Theresa Hahn|Lensa Idossa|Balkrishna Jahagirdar|Naynesh Kamani|Alison W. Loren|Deborah Mattila|Joseph P. McGuirk|Heather Moore|Jana Reynolds|Wael Saber|Lizette Salazar|Barry A. Schatz|Patrick J. Stiff|John R. Wingard|Karen L. Syrjala|K. Scott Baker
Randomized controlled trial of individualized treatment summary and survivorship care plans for hematopoietic cell transplantation survivors
Cleveland Clinic|National Marrow Donor Program|Medical College of Wisconsin|National Marrow Donor Program|National Marrow Donor Program|Leukemia and Lymphoma Society|National Marrow Donor Program|National Marrow Donor Program|National Marrow Donor Program|UMass Memorial Health Care|UMass Memorial Medical Center|National Marrow Donor Program|Roswell Park Comprehensive Cancer Center|National Marrow Donor Program|Regions Hospital|American Association of Blood Banks|University of Pennsylvania|National Marrow Donor Program|University of Kansas Medical Center|National Marrow Donor Program|Baylor University Medical Center|Medical College of Wisconsin|Loyola University Medical Center|Loyola University Medical Center|University of Florida|Fred Hutch Cancer Center|Fred Hutch Cancer Center
survivorship care plans scps may facilitate longterm care cancer survivors effectiveness established hematopoietic cell transplantation recipients evaluated impact individualized scps patientreported outcomes among transplant survivors adult 18 years transplant survivors 15 years post transplantation proficient english without relapse secondary cancers eligible multicenter randomized trial scps developed based riskfactors treatment exposures using patient data routinely submitted transplant centers center international blood marrow transplant research published guidelines longterm follow transplant survivors phone surveys assessing patientreported outcomes conducted baseline 6 months primary end point confidence survivorship information secondary end points included cancer treatment distress knowledge transplant exposures health care utilization healthrelated quality life 495 patients enrolled 458 completed baseline survey randomized care plan231 standard care227 200 87 199 88 completed 6month assessments respectively patients characteristics similar two arms participants care plan arm reported significantly lower distress scores 6 months increase mental component summary quality life score assessed short form 12 sf12 instrument effect observed end point confidence survivorship information secondary outcomes provision individualized scps generated using registry data associated reduced distress improved mental domain quality life among 15 year hematopoietic cell transplantation survivors trial registered clinicaltrialsgov 02200133